Antiplatelet, anticoagulant, and thrombolytic drug interactions.
Iqbal
Omer
O
Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.
Mousa
Shaker A
SA
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013916:Thrombelastography
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex